Fidson Healthcare Plc, a Nigerian pharmaceutical company, has signed a strategic cooperation agreement with Jiangsu Aidea Pharmaceutical Company, an innovative pharmaceutical company based in Yangzhou, China.

The agreement was signed on November 13, 2023 in Yangzhou, China and this information was contained in a report on the Nigerian Exchange Group (NGX).

The agreement aims to promote and address medical challenges through the use of innovative drugs, especially in the treatment of over 1.9 million HIV-infected people in Nigeria.

The MoU read in parts: ‘‘The two companies agreed to share and combine the respective resources, technical expertise and positions in the market to collaborate on project development, market expansion and other aspects by integrating their competitive advantages in the pharmaceutical field. Both companies will engage in multi-level and product manufacturing, promotions and sales, and clinical research involving existing products and pipeline projects.

‘’The collaboration holds promise as a significant growth driver for both companies, particularly as a major factor in the development of local pharmaceutical manufacturing in Nigeria. It will also improve the healthcare and medical practice on the continent and is expected to be a sterling example of in-depth cooperation in the medical field between China and Nigeria’’.

Related News

Furthermore, at the signing ceremony, Dr. Heliang Fu, chairman of Aidea Pharma noted that the collaboration marks an important step for the company in its commitment to global medical cooperation.

He said, ‘’By integrating our expertise and experience in the field of innovative drugs, we are confident in bringing greater well-being to African patients’’.

Dr. Fidelis Ayebae, managing director and CEO of Fidson also expressed excitement about the collaboration especially with the complementary strengths and the capacity of both parties to inject new vitality into the medical field in Africa. He declared that the deal was ‘’To provide better and more accessible medicines for the people of Africa.’’

Fidson Healthcare Plc is a company that is mainly engaged in the production and sales of high-quality medicines and healthcare products. It was also the first to manufacture anti-retroviral (ARV) drugs in Sub-Saharan Africa in 2005. The company was established in 1995.

Jiangsu Aidea Pharmaceuticals is a company that focuses on the core development area of anti-HIV drugs and also leverages its competitive advantages in the field of human protein. The firm is committed to research and development, building a complete pipeline of antiretroviral drugs (ARV) and has core technical and product first-mover advantage.